Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Moody's
MCO
5
Jefferies Financial
JEF
CN Stock MarketDetailed Quotes
688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
- 7.83
- +0.22+2.89%
Market Closed Apr 30 15:00 CST
8.12BMarket Cap200.77P/E (TTM)
7.88High7.66Low35.38KlotVolume7.68Open7.61Pre Close27.51MTurnover0.50%Turnover Ratio206.05P/E (Static)1.04BShares10.2952wk High3.52P/B5.56BFloat Cap6.0252wk Low9.13Limit Up710.57MShs Float42.07Historical High6.09Limit Down2.89%Amplitude6.02Historical Low0.09Dividend TTM7.78Avg Price14.92KlotAsk1.15%Div YieldTTM100Lot Size20.15KlotBid
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. News
Fudan-Zhangjiang Bio-Pharmaceutical's Q2 Sales to Be Hit By Product Price Cuts
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK): The price reduction of Libaidu is not less than 35% compared to the previous bidding price.
Gelonghui reported on April 30 that Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced that its nanotechnology platform's antitumor drug, Doxorubicin Liposome Injection (trademark name: Liposomal Doxorubicin), was launched in August 2009. It is the first domestic generic of Doxil/Caelyx and the first generic nanodrug in both domestic and international markets. This drug utilizes advanced stealth liposome technology for encapsulation and features passive targeting characteristics. It represents an upgraded formulation of anthracycline drugs, offering advantages in cancer treatment, including enhanced efficacy, reduced cardiotoxicity, bone marrow suppression, and decreased hair loss.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (688505.SH) reported a net income of 2.6651 million yuan in the first quarter, with a year-on-year growth of 13.53%.
Gelonghui, April 29丨Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (688505.SH) released its first-quarter report, achieving total operating income of 0.18 billion yuan in the first quarter of 2025, a year-on-year increase of 21.85%; the net income attributable to shareholders of the parent company was 2.6651 million yuan, a year-on-year increase of 13.53%; the EPS was 0 yuan.
Fudan Zhangjiang: Fudan Zhangjiang Report for the First Quarter of 2025
Fudan Zhangjiang Report for the First Quarter of 2025
Fudan-Zhangjiang Bio-Pharmaceutical's Q1 Profit Rises 14%
FUDANZHANGJIANG: NOTICE OF ANNUAL GENERAL MEETING
In the first quarter, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. had a net income of 2.665 million yuan, a year-on-year increase of 13.53%.
Gelonghui reported on April 28 that Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced that in the first quarter of 2025, the company's revenue was 0.18 billion yuan, an increase of 21.85% year-on-year; the Net income attributable to shareholders of the listed company was 2.665 million yuan, a year-on-year increase of 13.53%; during the period, the Net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was a loss of 3.3 million yuan.
FUDANZHANGJIANG: ANNUAL REPORT 2024
FUDANZHANGJIANG: THE FIRST QUARTERLY RESULTS ANNOUNCEMENT FOR THE THREE MONTHS ENDED 31 MARCH 2025
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) will hold a Board of Directors meeting on April 28 to approve the first quarter performance.
Gelonghui, April 14 – Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced that a Board of Directors meeting will be held on Monday, April 28, 2025, to review and approve (including) the unaudited performance of the company and its subsidiaries for the first quarter ending March 31, 2025, and its release.
The Five-year Shareholder Returns and Company Earnings Persist Lower as Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) Stock Falls a Further 15% in Past Week
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Fudan-Zhangjiang Bio-Pharmaceutical Invests 200 Million Yuan in Structured Deposit Product
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK): subscribed to 0.22 billion yuan Shanghai Pudong Development Bank structured deposit products.
Gelonghui, April 1st | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (01349.HK) announced that recently, the company signed a structured deposit product agreement with Shanghai Pudong Development Bank, agreeing to purchase structured deposit products totaling 0.22 billion yuan with idle funds generated from daily operations.
Express News | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical- to Subscribe for Structured Deposit Product of RMB220 Mln From Spd Bank
Fudan Zhangjiang: Fudan Zhangjiang 2024 Annual Report Summary
Fudan Zhangjiang: Fudan Zhangjiang 2024 Annual Report
Fudan Zhangjiang 2024 Annual Report
Fudan Zhangjiang 2024 Annual Report Summary
Market Insights
Warren Buffett Portfolio Warren Buffett Portfolio
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
Unlock Now
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts